US5632778A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treated tissue for implantation and methods of preparation
Assignee: Artivion Inc
•
Filing: 1995-06-05
•
Granted: 1997-05-27
•
Expires: 2015-06-05
Abstract
Abstract This disclosure includes a method for generating a functional hybrid bioprosthesis. Tissue formed naturally of interstitial collagens is treated to kill native cells and remove potentially immunologically active soluble molecules. Then it may be treated sequentially with extracellular matrix adhesion factor, extracellular matrix glycosaminoglycan, and growth factor appropriate to the cell type required to function within the matrix, and incubating the transplant tissue matrix with cells that are either allogeneic or autologous for the recipient thereby imparting to the matrix the characteristics of the cell type and tissue selected. Tissues with a variety of functional bioactivities can thus be formed in vitro prior to graft transplantation or implantation which will exhibit reduced or no stimulation of an immunological response in the recipient.
Inventors
- 👤 Steven Goldstein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 05:08
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/3683; A61L27/3687; A61L27/3604; A61L27/3625; A61L27/38; A61L27/3804; A61L27/3895; A61L27/50; A61L27/507; A61L2430/00; A61L2430/40; Y; Y10; Y10S; Y10S623/00; Y10S623/92; Y10S623/921
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
105 words
A process for generating a substantially non-immunogenic tissue matrix suitable for subsequent processing into an implant tissue comprising: A. eliminating native cells by treating a tissue with components selected from the group consisting enzymes and nucleases effective to inhibit subsequent native cell growth in the treated tissue and effective to limit generation of new immunological sites in the tissue thus producing a tissue matrix; B. treating the tissue matrix with cellular adhesion factor to promote subsequent attachment of cultured allogeneic or autologous cells to the surfaces of the tissue matrix; and C. repopulating the tissue matrix throughout the matrix with cultured allogeneic or autologous cells.
Claim 2
Dependent Claim
105 words
A process for generating a substantially non-immunogenic tissue matrix suitable for subsequent processing into an implant tissue comprising: A. eliminating native cells by treating a tissue with components selected from the group consisting enzymes and nucleases effective to inhibit subsequent native cell growth in the treated tissue and effective to limit generation of new immunological sites in the tissue thus producing a tissue matrix; B. treating the tissue matrix with cellular adhesion factor to promote subsequent attachment of cultured allogeneic or autologous cells to the surfaces of the tissue matrix; and C. repopulating the tissue matrix throughout the matrix with cultured allogeneic or autologous cells.
Claim 3
Dependent Claim
34 words
The process of claim 1 wherein, during step A, the tissue is treated with a low ionic strength solution of nucleases effective to decellularize the tissue and provide a tissue matrix of limited immunogenicity.
Claim 4
Dependent Claim
33 words
The process of claim 2 wherein the low ionic strength solution of nucleases includes at least one member, selected from the group consisting of RNAase A, DNAase I, EcoR I and Hind III.
Claim 5
Dependent Claim
15 words
The process of claim 2 wherein the nucleases employed are ribonuclease A and deoxyribonuclease I.
Claim 6
Dependent Claim
19 words
The process of claim 1 further comprising cryopreserving the tissue matrix after step A and prior to further processing.
Claim 7
Dependent Claim
19 words
The process of claim 2 further comprising cyropreserving the tissue matrix after step A and prior to further processing.
Claim 8
Dependent Claim
15 words
The process of claim 5 further comprising sterilizing the tissue or tissue matrix or both.
Claim 9
Dependent Claim
32 words
The process of claim 1 wherein the process further comprises obtaining natural mammalian tissue, cryopreserving the tissue, removing the tissue from cryopreservation and then treating the tissue in accordance with claim 1.
Claim 10
Dependent Claim
14 words
The process of claim 8 wherein the tissue is of porcine heart valve origin.
Claim 11
Dependent Claim
17 words
The process of claim 9 wherein the heart valve is a pulmonary or an aortic heart valve.
Claim 12
Dependent Claim
16 words
The process of claim 1 wherein step A further comprises treatment with a hypotonic aqueous solution.
Claim 13
Dependent Claim
20 words
The process of claim 11 herein said hypotonic aqueous solution is a buffered aqueous solution effective to cause cell lysis.
Claim 14
Dependent Claim
13 words
The process of claim 12 wherein the tissue is porcine heart valve tissue.
Claim 15
Dependent Claim
17 words
The process of claim 13 wherein the heart valve is a pulmonary or an aortic heart valve.
Claim 16
Dependent Claim
21 words
The process of claim 14 further comprising the step of cryopreserving the porcine heart valve tissue matrix produced by step A.
References Cited (Backward Citations)
FR1522286A
Cited
FR2104349A5
Cited
US3966401A
Cited
US4083066A
Cited
US4240794A
Cited
US4383832A
Cited
US4378224A
Cited
US4407787A
Cited
US4539716A
Cited
US4323358A
Cited
US4546500A
Cited
US4485096A
Cited
US4647283A
Cited
WO1983003335A1
Cited
US4648881A
Cited
US4405327A
Cited
US4402697A
Cited
US4973493A
Cited
WO1984001879A1
Cited
US5215541A
Cited
US4559298A
Cited
GB2136533A
Cited
US4642120A
Cited
US4801299A
Cited
EP0128706A2
Cited
US4567847A
Cited
US4865871A
Cited
US4799361A
Cited
US4609551A
Cited
US4553974A
Cited
WO1986002273A1
Cited
US4785079A
Cited
US4828563A
Cited
FR2589165A1
Cited
US4688387A
Cited
US4911710A
Cited
US4776853A
Cited
WO1988002263A1
Cited
US4798611A
Cited
EP0267026A2
Cited
US4707998A
Cited
US4902782A
Cited
US4890457A
Cited
US4835102A
Cited
US4838888A
Cited
EP0296475A1
Cited
WO1989000198A1
Cited
US4870160A
Cited
WO1989001286A1
Cited
US4878913A
Cited
WO1989008117A1
Cited
US4950483A
Cited
US4960424A
Cited
EP0361957A1
Cited
US5002566A
Cited
US4964280A
Cited
US5131850A
Cited
WO1991016009A1
Cited
WO1991018505A1
Cited
US5145770A
Cited
US5336616A
Cited
US5197985A
Cited
US5192312A
Cited
US5512474A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-05-26 | 2000-11-25 | 2001-05-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-05-26 | 2004-11-25 | 2005-05-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-05-26 | 2008-11-25 | 2009-05-27 | $7700.00 | Window Closed / Lapsed |